CLONIDINE patch adverse reactions: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Clonidine}} {{CMG}}; {{AE}} {{PB}} '''''For patient information, click here'''''. ==Adverse Reactions== <ref name="dailymed...")
 
Line 7: Line 7:
==Adverse Reactions==
==Adverse Reactions==


====Clinical trial experience with Clonidine Transdermal System====


<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = CLONIDINE PATCH [MYLAN PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7adfc439-e6d0-4593-87dd-0eef36d33c6d | publisher =  | date =  | accessdate = 5 February 2014 }}</ref>
Most systemic adverse effects during Clonidine Transdermal System therapy have been mild and have tended to diminish with continued therapy. In a 3-month multiclinic trial of Clonidine Transdermal System in 101 hypertensive patients, the systemic adverse reactions were, dry mouth (25 patients) and drowsiness (12), fatigue (6), headache (5), lethargy and sedation (3 each), insomnia, [[dizziness]], [[impotence]]/[[sexual dysfunction]], dry throat (2 each) and [[constipation]], [[nausea]], change in taste and nervousness (1 each).


In the above mentioned 3-month controlled clinical trial, as well as other uncontrolled clinical trials, the most frequent adverse reactions were dermatological and are described below.
In the 3-month trial, 51 of the 101 patients had localized skin reactions such as [[erythema]] (26 patients) and/or [[pruritus]], particularly after using an adhesive cover throughout the 7-day dosage interval. Allergic contact sensitization to Clonidine Transdermal System was observed in 5 patients. Other skin reactions were localized vesiculation (7 patients), [[hyperpigmentation]] (5), [[edema]] (3), [[excoriation]] (3), burning (3), [[papules]] (1), throbbing (1), blanching, and a generalized macular rash.
In additional clinical experience, contact dermatitis resulting in treatment discontinuation was observed in 128 of 673 patients (about 19 in 100) after a mean duration of treatment of 37 weeks. The incidence of contact dermatitis was about 34 in 100 among white women, about 18 in 100 in white men, about 14 in 100 in black women, and approximately 8 in 100 in black men. Analysis of skin reaction data showed that the risk of having to discontinue Clonidine Transdermal System treatment because of contact dermatitis was greatest between treatment weeks 6 and 26, although sensitivity may develop either earlier or later in treatment.
In a large-scale clinical acceptability and safety study by 451 physicians in a total of 3,539 patients, other allergic reactions were recorded for which a causal relationship to Clonidine Transdermal System was not established: [[maculopapular rash]] (10 cases); urticaria (2 cases); and [[angioedema]] of the face (2 cases), which also affected the tongue in one of the patients.
====Marketing Experience with Clonidine Transdermal System====
The following adverse reactions have been identified during post-approval use of Clonidine Transdermal System. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to Clonidine Transdermal System.
Body as a Whole: [[Fever]]; [[malaise]]; weakness; [[pallor]]; and withdrawal syndrome.
====Cardiovascular====
[[Congestive heart failure]]; [[cerebrovascular accident]]; electrocardiographic abnormalities (i.e., [[bradycardia]], [[sick sinus syndrome]] disturbances and [[arrhythmias]]); [[chest pain]]; orthostatic symptoms; [[syncope]]; increases in blood pressure; [[sinus bradycardia]] and atrioventricular (AV) block with and without the use of concomitant [[digitalis]]; [[Raynaud’s phenomenon]]; [[tachycardia]]; [[bradycardia]]; and [[palpitations]].
====Central and Peripheral Nervous System/Psychiatric====
[[Delirium]]; mental [[depression]]; [[hallucinations]] (including visual and auditory); localized numbness; vivid dreams or nightmares; restlessness; anxiety; agitation; irritability; other behavioral changes; and drowsiness.
====Dermatological====
[[Angioneurotic edema]]; localized or generalized rash; [[hives]]; [[urticaria]]; [[contact dermatitis]]; [[pruritus]]; [[alopecia]]; and localized hypo or [[hyper pigmentation]].
====Gastrointestinal====
[[Anorexia]] and [[vomiting]].
====Genitourinary====
Difficult micturition; loss of libido; and decreased sexual activity.
====Metabolic====
[[Gynecomastia]] or breast enlargement and weight gain.
====Musculoskeletal====
Muscle or joint pain; and leg cramps.
====Ophthalmological====
Blurred vision; burning of the eyes and dryness of the eyes.
===Adverse Events Associated with Oral Clonidine Therapy===
Most adverse effects are mild and tend to diminish with continued therapy. The most frequent (which appear to be dose-related) are dry mouth, occurring in about 40 of 100 patients; drowsiness, about 33 in 100; dizziness, about 16 in 100; constipation and sedation, each about 10 in 100. The following less frequent adverse experiences have also been reported in patients receiving clonidine hydrochloride, USP tablets, but in many cases patients were receiving concomitant medication and a causal relationship has not been established.
====Body as a Whole: Fatigue====
[[fever]], [[headache]], [[pallor]], weakness, and withdrawal syndrome. Also reported were a weakly positive [[Coombs’ test]] and increased sensitivity to alcohol.
====Cardiovascular==== [[Bradycardia]], [[congestive heart failure]], electrocardiographic abnormalities (i.e., sinus node arrest, junctional [[bradycardia]], high degree [[AV block]] and [[arrhythmias]]), orthostatic symptoms, [[palpitations]], [[Raynaud’s phenomenon]], [[syncope]], and [[tachycardia]]. Cases of sinus [[bradycardia]] and [[AV block]] have been reported, both with and without the use of concomitant [[digitalis]].
====Central Nervous System====
[[Agitation]], [[anxiety]], [[delirium]], delusional perception, [[hallucinations]] (including visual and auditory), [[insomnia]], mental [[depression]], nervousness, other behavioral changes, [[paresthesia]], restlessness, [[sleep disorder]], and vivid dreams or nightmares.
====Dermatological====
[[Alopecia]], angioneurotic edema, [[hives]], [[pruritus]], [[rash]], and [[urticaria]].
====Gastrointestinal====
Abdominal pain, [[anorexia]], [[constipation]], [[hepatitis]], [[malaise]], mild transient abnormalities in liver function tests, [[nausea]], [[parotitis]], pseudo-obstruction (including colonic pseudo-obstruction), salivary gland pain, and [[vomiting]].
====Genitourinary====
Decreased sexual activity, difficulty in micturition, erectile dysfunction, loss of libido, [[nocturia]], and urinary retention.
====Hematologic====
[[Thrombocytopenia]].
====Metabolic====
[[Gynecomastia]], transient elevation of blood glucose or serum [[creatine phosphokinase]], and weight gain.
====Musculoskeletal====
Leg cramps and muscle or joint pain.
====Oro-otolaryngeal====
Dryness of the nasal mucosa.
====Ophthalmological====
Accommodation disorder, blurred vision, burning of the eyes, decreased lacrimation, and dryness of the eyes.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = CLONIDINE PATCH [MYLAN PHARMACEUTICALS INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7adfc439-e6d0-4593-87dd-0eef36d33c6d | publisher =  | date =  | accessdate = 5 February 2014 }}</ref>


==References==
==References==

Revision as of 02:10, 6 February 2014

Clonidine
CATAPRES® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
CLONIDINE patch ® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
DURACLON (clonidine hydrochloride) injection® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Clonidine
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Pratik Bahekar, MBBS [2]

For patient information, click here.

Adverse Reactions

Clinical trial experience with Clonidine Transdermal System

Most systemic adverse effects during Clonidine Transdermal System therapy have been mild and have tended to diminish with continued therapy. In a 3-month multiclinic trial of Clonidine Transdermal System in 101 hypertensive patients, the systemic adverse reactions were, dry mouth (25 patients) and drowsiness (12), fatigue (6), headache (5), lethargy and sedation (3 each), insomnia, dizziness, impotence/sexual dysfunction, dry throat (2 each) and constipation, nausea, change in taste and nervousness (1 each).

In the above mentioned 3-month controlled clinical trial, as well as other uncontrolled clinical trials, the most frequent adverse reactions were dermatological and are described below.

In the 3-month trial, 51 of the 101 patients had localized skin reactions such as erythema (26 patients) and/or pruritus, particularly after using an adhesive cover throughout the 7-day dosage interval. Allergic contact sensitization to Clonidine Transdermal System was observed in 5 patients. Other skin reactions were localized vesiculation (7 patients), hyperpigmentation (5), edema (3), excoriation (3), burning (3), papules (1), throbbing (1), blanching, and a generalized macular rash.

In additional clinical experience, contact dermatitis resulting in treatment discontinuation was observed in 128 of 673 patients (about 19 in 100) after a mean duration of treatment of 37 weeks. The incidence of contact dermatitis was about 34 in 100 among white women, about 18 in 100 in white men, about 14 in 100 in black women, and approximately 8 in 100 in black men. Analysis of skin reaction data showed that the risk of having to discontinue Clonidine Transdermal System treatment because of contact dermatitis was greatest between treatment weeks 6 and 26, although sensitivity may develop either earlier or later in treatment.

In a large-scale clinical acceptability and safety study by 451 physicians in a total of 3,539 patients, other allergic reactions were recorded for which a causal relationship to Clonidine Transdermal System was not established: maculopapular rash (10 cases); urticaria (2 cases); and angioedema of the face (2 cases), which also affected the tongue in one of the patients.

Marketing Experience with Clonidine Transdermal System

The following adverse reactions have been identified during post-approval use of Clonidine Transdermal System. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. Decisions to include these reactions in labeling are typically based on one or more of the following factors: (1) seriousness of the reaction, (2) frequency of reporting, or (3) strength of causal connection to Clonidine Transdermal System.

Body as a Whole: Fever; malaise; weakness; pallor; and withdrawal syndrome.

Cardiovascular

Congestive heart failure; cerebrovascular accident; electrocardiographic abnormalities (i.e., bradycardia, sick sinus syndrome disturbances and arrhythmias); chest pain; orthostatic symptoms; syncope; increases in blood pressure; sinus bradycardia and atrioventricular (AV) block with and without the use of concomitant digitalis; Raynaud’s phenomenon; tachycardia; bradycardia; and palpitations.

Central and Peripheral Nervous System/Psychiatric

Delirium; mental depression; hallucinations (including visual and auditory); localized numbness; vivid dreams or nightmares; restlessness; anxiety; agitation; irritability; other behavioral changes; and drowsiness.

Dermatological

Angioneurotic edema; localized or generalized rash; hives; urticaria; contact dermatitis; pruritus; alopecia; and localized hypo or hyper pigmentation.

Gastrointestinal

Anorexia and vomiting.

Genitourinary

Difficult micturition; loss of libido; and decreased sexual activity.

Metabolic

Gynecomastia or breast enlargement and weight gain.

Musculoskeletal

Muscle or joint pain; and leg cramps.

Ophthalmological

Blurred vision; burning of the eyes and dryness of the eyes.

Adverse Events Associated with Oral Clonidine Therapy

Most adverse effects are mild and tend to diminish with continued therapy. The most frequent (which appear to be dose-related) are dry mouth, occurring in about 40 of 100 patients; drowsiness, about 33 in 100; dizziness, about 16 in 100; constipation and sedation, each about 10 in 100. The following less frequent adverse experiences have also been reported in patients receiving clonidine hydrochloride, USP tablets, but in many cases patients were receiving concomitant medication and a causal relationship has not been established.

Body as a Whole: Fatigue

fever, headache, pallor, weakness, and withdrawal syndrome. Also reported were a weakly positive Coombs’ test and increased sensitivity to alcohol.

====Cardiovascular==== Bradycardia, congestive heart failure, electrocardiographic abnormalities (i.e., sinus node arrest, junctional bradycardia, high degree AV block and arrhythmias), orthostatic symptoms, palpitations, Raynaud’s phenomenon, syncope, and tachycardia. Cases of sinus bradycardia and AV block have been reported, both with and without the use of concomitant digitalis.

Central Nervous System

Agitation, anxiety, delirium, delusional perception, hallucinations (including visual and auditory), insomnia, mental depression, nervousness, other behavioral changes, paresthesia, restlessness, sleep disorder, and vivid dreams or nightmares.

Dermatological

Alopecia, angioneurotic edema, hives, pruritus, rash, and urticaria.

Gastrointestinal

Abdominal pain, anorexia, constipation, hepatitis, malaise, mild transient abnormalities in liver function tests, nausea, parotitis, pseudo-obstruction (including colonic pseudo-obstruction), salivary gland pain, and vomiting.

Genitourinary

Decreased sexual activity, difficulty in micturition, erectile dysfunction, loss of libido, nocturia, and urinary retention.

Hematologic

Thrombocytopenia.

Metabolic

Gynecomastia, transient elevation of blood glucose or serum creatine phosphokinase, and weight gain.

Musculoskeletal

Leg cramps and muscle or joint pain.

Oro-otolaryngeal

Dryness of the nasal mucosa.

Ophthalmological

Accommodation disorder, blurred vision, burning of the eyes, decreased lacrimation, and dryness of the eyes.[1]

References

  1. "CLONIDINE PATCH [MYLAN PHARMACEUTICALS INC.]". Retrieved 5 February 2014.

Template:Antimigraine preparations